BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.40% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.50%, a 6.25% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-03-31 was 1.60%, a 166.67% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2013-03-31 was 0.60%, a 33.33% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2012-03-31 was 0.90%.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.40%, a 12.50% decline from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.60%, a 0.00% change from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 1.60%, a 128.57% increase from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2013 was 0.70%, a 22.22% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2016-12-31 | 1.40% 10-K · filed 2017-02-27 | ||||
| 2015-12-31 | 1.60% 10-K · filed 2017-02-27 | ||||
| 2015-09-30 | 1.50% 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | 1.50% 10-Q · filed 2015-08-07 | ||||
| 2015-03-31 | 1.50% 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | 1.60% 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | 1.60% 10-Q · filed 2015-11-06 | ||||
| 2014-06-30 | 1.60% 10-Q · filed 2015-08-07 | ||||
| 2014-03-31 | 1.60% 10-Q · filed 2015-05-08 | 1.60% 10-Q · filed 2014-08-08 | |||
| 2013-12-31 | 0.70% 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | 0.90% 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | 0.60% 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | 0.60% 10-Q · filed 2014-05-09 | 0.60% 10-Q · filed 2014-08-08 | |||
| 2012-12-31 | 0.90% 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | 0.86% 10-Q · filed 2013-11-08 | ||||
| 2012-06-30 | 0.90% 10-Q · filed 2013-08-08 | 0.89% 10-Q · filed 2012-08-08 | |||
| 2012-03-31 | 0.90% 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | 2.20% 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | 2.20% 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | 2.20% 10-Q · filed 2012-08-08 | ||||
| 2010-12-31 | 2.40% 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |